Key Points
- SVP insider selling: Zurit Levine sold 5,375 shares on April 8 at an average of $2.42 under a pre-arranged Rule 10b5-1 plan, trimming her stake by 15.47% to 29,375 shares; including April 1 and April 7 trades she sold a total of 11,375 shares in early April.
- Strong recent results and market reaction: CGEN opened at $2.48 (up ~8.3%), market cap ~$234.5M, and posted a big quarter—$0.60 EPS vs $0.05 consensus and $67.33M revenue vs $14.3M expected—boosting investor interest.
Compugen Ltd. (NASDAQ:CGEN - Get Free Report) SVP Zurit Levine sold 5,375 shares of the business's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $2.42, for a total transaction of $13,007.50. Following the completion of the transaction, the senior vice president owned 29,375 shares in the company, valued at $71,087.50. This trade represents a 15.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Zurit Levine also recently made the following trade(s):
- On Tuesday, April 7th, Zurit Levine sold 2,500 shares of Compugen stock. The stock was sold at an average price of $2.30, for a total value of $5,750.00.
- On Wednesday, April 1st, Zurit Levine sold 3,500 shares of Compugen stock. The stock was sold at an average price of $2.20, for a total value of $7,700.00.
Compugen Trading Up 8.3%
CGEN stock opened at $2.48 on Friday. The stock has a 50-day moving average price of $1.99 and a 200-day moving average price of $1.80. Compugen Ltd. has a 1-year low of $1.15 and a 1-year high of $2.49. The firm has a market cap of $234.48 million, a PE ratio of 6.70 and a beta of 2.77.
Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.55. The firm had revenue of $67.33 million during the quarter, compared to analyst estimates of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. On average, analysts forecast that Compugen Ltd. will post -0.03 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP lifted its stake in Compugen by 135.7% in the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company's stock worth $163,000 after purchasing an additional 61,202 shares during the last quarter. State Street Corp raised its stake in shares of Compugen by 3.9% during the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company's stock valued at $603,000 after acquiring an additional 14,701 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Compugen by 3.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company's stock valued at $2,229,000 after acquiring an additional 51,565 shares during the last quarter. Jane Street Group LLC raised its stake in Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after buying an additional 359,785 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company's stock worth $291,000 after buying an additional 18,929 shares in the last quarter. 12.22% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on CGEN shares. HC Wainwright started coverage on Compugen in a research note on Wednesday, January 7th. They set a "buy" rating and a $4.00 price target for the company. Lake Street Capital began coverage on shares of Compugen in a report on Tuesday. They issued a "buy" rating and a $6.00 price target on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Compugen in a report on Wednesday, January 21st. Truist Financial raised shares of Compugen to a "strong-buy" rating in a report on Wednesday, March 25th. Finally, Wall Street Zen upgraded shares of Compugen from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.00.
Get Our Latest Research Report on Compugen
Compugen Company Profile
(
Get Free Report)
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
